CDMO News
Lonza and Acumen Partner for Alzheimer’s Treatment Manufacturing
Acumen Pharmaceuticals, a clinical-stage biopharmaceutical company, has entered into a manufacturing agreement with Lonza. The agreement covers the manufacture of sabirnetug (ACU193), an antibody targeting toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), for clinical
5 April 2024
Stay ahead of trends and best practices
